Molecular Targeting Technologies Inc. (MTTI) and Evergreen Theragnostics Inc., have entered an agreement in which Evergreen will manufacture MTTI’s EvaThera platform of radiopharmaceuticals.
 
The EvaThera platform is a new generation of Evans blue-based molecules with strong affinity for albumin, which extends the blood half-life of the radiopharmaceutical, potentially leading to improved outcomes. MTTI’s leading pipeline candidates are both Lu-177 based radiotherapeutics: EBTATE, targeting neuroendocrine and other SSTR2 expressing tumors, and EBRGD, targeting integrin expressing cancers like glioblastoma multiforme.
 
“The Evergreen team brings deep experience in manufacturing and nationwide distribution of Lu-177 products. This agreement is key to a robust and reliable supply in North America for our upcoming clinical trials and beyond,” said Chris Pak, president & CEO of MTTI.
 
Evergreen will manufacture MTTI clinical supplies from its newly commissioned facility in Springfield, NJ and will leverage the team’s broad experience with Lu-177 based radiotherapeutics by providing comprehensive supply chain management from isotope sourcing to drug delivery at the clinical trial site.
 
“We are very pleased to support MTTI by providing quality GMP manufacturing for their very promising platform of products. The technology behind the EvaThera platform has the potential to make a meaningful improvement in the lives of patients,” said James Cook, president & CEO of Evergreen.